Zurich Insurance Group Ltd FI boosted its stake in shares of Cardinal Health, Inc. (NYSE:CAH - Free Report) by 4,935.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 946,750 shares of the company's stock after purchasing an additional 927,950 shares during the quarter. Cardinal Health makes up approximately 1.1% of Zurich Insurance Group Ltd FI's holdings, making the stock its 21st largest position. Zurich Insurance Group Ltd FI owned approximately 0.40% of Cardinal Health worth $130,434,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Empowered Funds LLC boosted its position in Cardinal Health by 212.7% during the 1st quarter. Empowered Funds LLC now owns 93,561 shares of the company's stock worth $12,843,000 after acquiring an additional 63,637 shares during the period. Ascent Group LLC raised its stake in shares of Cardinal Health by 3.4% in the 1st quarter. Ascent Group LLC now owns 4,109 shares of the company's stock worth $566,000 after buying an additional 137 shares in the last quarter. MBB Public Markets I LLC acquired a new stake in shares of Cardinal Health during the first quarter worth $331,000. United Services Automobile Association acquired a new stake in shares of Cardinal Health during the first quarter worth $719,000. Finally, Great Lakes Advisors LLC raised its position in shares of Cardinal Health by 3.1% during the first quarter. Great Lakes Advisors LLC now owns 3,538 shares of the company's stock worth $487,000 after purchasing an additional 108 shares during the period. Institutional investors and hedge funds own 87.17% of the company's stock.
Cardinal Health Price Performance
Shares of NYSE CAH traded down $0.14 during trading hours on Friday, hitting $152.34. 1,162,569 shares of the company's stock were exchanged, compared to its average volume of 2,399,280. Cardinal Health, Inc. has a 1-year low of $106.54 and a 1-year high of $168.44. The stock has a market capitalization of $36.38 billion, a price-to-earnings ratio of 23.62, a PEG ratio of 1.26 and a beta of 0.73. The company's 50-day moving average price is $154.75 and its 200-day moving average price is $147.48.
Cardinal Health (NYSE:CAH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported $2.08 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.05. Cardinal Health had a negative return on equity of 74.45% and a net margin of 0.70%.The business had revenue of $60.16 billion during the quarter, compared to analysts' expectations of $60.91 billion. During the same quarter in the previous year, the firm earned $1.84 EPS. The firm's revenue was up .5% compared to the same quarter last year. Cardinal Health has set its FY 2026 guidance at 9.300-9.500 EPS. On average, research analysts expect that Cardinal Health, Inc. will post 7.95 earnings per share for the current year.
Cardinal Health Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Wednesday, October 1st will be given a dividend of $0.5107 per share. This represents a $2.04 annualized dividend and a dividend yield of 1.3%. The ex-dividend date of this dividend is Wednesday, October 1st. Cardinal Health's payout ratio is currently 31.63%.
Analyst Ratings Changes
A number of research analysts have recently weighed in on CAH shares. Robert W. Baird lifted their price target on Cardinal Health from $197.00 to $203.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. Jefferies Financial Group set a $150.00 target price on Cardinal Health in a research note on Tuesday, August 12th. Wells Fargo & Company restated an "overweight" rating and issued a $185.00 target price (up previously from $183.00) on shares of Cardinal Health in a research note on Wednesday, August 13th. Leerink Partners lowered their target price on Cardinal Health from $188.00 to $186.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 12th. Finally, Argus set a $189.00 target price on Cardinal Health in a research note on Friday, August 22nd. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $165.93.
Check Out Our Latest Analysis on CAH
Insider Buying and Selling at Cardinal Health
In other Cardinal Health news, CEO Stephen M. Mason sold 41,575 shares of the company's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $148.82, for a total value of $6,187,191.50. Following the completion of the transaction, the chief executive officer owned 26,085 shares of the company's stock, valued at $3,881,969.70. This represents a 61.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jason M. Hollar sold 107,705 shares of the company's stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $148.90, for a total value of $16,037,274.50. Following the completion of the transaction, the chief executive officer directly owned 235,901 shares of the company's stock, valued at approximately $35,125,658.90. This trade represents a 31.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 271,676 shares of company stock worth $40,489,525 in the last ninety days. 0.09% of the stock is owned by insiders.
Cardinal Health Profile
(
Free Report)
Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.
Read More

Before you consider Cardinal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.
While Cardinal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report